Carisbamate
Epilepsy, Simple Partial
SK Life Science, Inc.Small moleculePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Epilepsy, Simple Partial cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fycompa Chinese University of Hong Kong | NR | |
Remegal Valexfarm | Phase 3 | NR |
Same molecule, other indications
Carisbamate is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →